US5466786A
Expired / Lapsed
US
⏱️ 0.0 years remaining
2'modified nucleoside and nucleotide compounds
Assignee: Ionis Pharmaceuticals Inc
•
Filing: 1994-05-10
•
Granted: 1995-11-14
•
Expires: 2014-05-10
Abstract
Abstract Oligomers which have substituents on the 2' position are resistant to oligonucleases and furthermore can be derivatized to deliver reagents or drugs, to carry label, or to provide other properties.
Inventors
- 👤 Chris A. Buhr
- 👤 Mark Matteucci
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-29 14:36
CPC Classifications
C; C12; C12N; C12N15/00; C12N15/09; C12N15/11; C12N15/113; C07; C07H; C07H19/00; C07H19/02; C07H19/04; C07H19/06; C07H19/10; C07H19/16; C07H19/20; C07H21/00; C12N2310/00; C12N2310/30; C12N2310/32; C12N2310/321; C12N2310/322; C12N2310/35; C12N2310/351; C12N2310/3517; C12N2310/352; C12N2310/3527; C12N2310/353; C12N2310/3535
Claims Analysis
Total Claims: 10
Claim 1
Independent Claim
197 words
A monomer having the formula: ##STR7## wherein B is a purine or pyrimidine moiety; W 1 is H, (PO 3 ) m -2 wherein m is an integer of 1-3; a protecting group, or an intermediate moiety in the formation of an internucleotide link which when reacted with the appropriate --OH results in Z wherein Z is selected from the group consisting of P(O)O -- , P(O)S, P(O)NR 2 , P(O)R, P(O)OR', CO, and CNR 2 , wherein R is H or alkyl (1-6 C) and R' is alkyl (1-6 C); W 2 is H, PO 3 -2 a protecting group or an intermediate moiety in the formation of an internucleotide link which when reacted with the appropriate --OH results in Z wherein Z is selected from the group consisting of P(O)O -- , P(O)S, P(O)NR 2 , P(O)R, P(O)OR', CO, and CNR 2 , wherein R is H or alkyl (1-6 C) and R' is alkyl (1-6 C); X is O, S, NR, or CR 2 wherein each R is independently H or alkyl (1-6 C); Y is a drug moiety selected from the group consisting of netropsin, anthramycin, quinoxaline antibiotics, actinomycin, and pyrrolo (1-4) benzodiazepine.
Claim 2
Dependent Claim
197 words
A monomer having the formula: ##STR7## wherein B is a purine or pyrimidine moiety; W 1 is H, (PO 3 ) m -2 wherein m is an integer of 1-3; a protecting group, or an intermediate moiety in the formation of an internucleotide link which when reacted with the appropriate --OH results in Z wherein Z is selected from the group consisting of P(O)O -- , P(O)S, P(O)NR 2 , P(O)R, P(O)OR', CO, and CNR 2 , wherein R is H or alkyl (1-6 C) and R' is alkyl (1-6 C); W 2 is H, PO 3 -2 a protecting group or an intermediate moiety in the formation of an internucleotide link which when reacted with the appropriate --OH results in Z wherein Z is selected from the group consisting of P(O)O -- , P(O)S, P(O)NR 2 , P(O)R, P(O)OR', CO, and CNR 2 , wherein R is H or alkyl (1-6 C) and R' is alkyl (1-6 C); X is O, S, NR, or CR 2 wherein each R is independently H or alkyl (1-6 C); Y is a drug moiety selected from the group consisting of netropsin, anthramycin, quinoxaline antibiotics, actinomycin, and pyrrolo (1-4) benzodiazepine.
Claim 3
Dependent Claim
11 words
The monomer of claim 1 wherein X is O or S.
Claim 4
Dependent Claim
9 words
The monomer of claim 1 wherein X is NR.
Claim 5
Dependent Claim
11 words
The monomer of claim 1 wherein X is CR 2 .
Claim 6
Dependent Claim
16 words
The monomer of claim 1 wherein W 2 is a phosphonate moiety or a salt thereof.
Claim 7
Dependent Claim
12 words
The monomer of claim 1 wherein W 1 is a protecting group.
Claim 8
Dependent Claim
12 words
The monomer of claim 5 wherein said salt is a triethylammonium salt.
Claim 9
Dependent Claim
252 words
A monomer having the formula: ##STR8## wherein B is a purine or pyrimidine moiety; W 1 is H, (PO 3 ) m -2 wherein m is an integer of 1-3; a protecting group, or an intermediate moiety in the formation of an internucleotide link which when reacted with the appropriate --OH results in Z wherein Z is selected from the group consisting of P(O)O -- , P(O)S, P(O)NR 2 , P(O)R, P(O)OR', CO, and CNR 2 , wherein R is H or alkyl (1-6 C) and R' is alkyl (1-6 C); W 2 is H, PO 3 -2 a protecting group, or an intermediate moiety in the formation of an internucleotide link which when reacted with the appropriate --OH results in Z wherein Z is selected from the group consisting of P(O)O -- , P(O)S, P(O)NR 2 , P(O)R, P(O)OR', CO, and CNR 2 , wherein R is H or alkyl (1-6 C) and R' is alkyl (1-6 C); X is O, S or CR 2 wherein each R is independently H or alkyl (1-6 C); Y is selected from the group consisting of substituted or unsubstituted alkyl (2-20 C), substituted or unsubstituted alkenyl (2-20 C), substituted or unsubstituted aryl (6-20 C), wherein the substituents are selected from the group consisting of a hydroxyl, an amino, a mercaptyl, a carboxy or a keto moiety, --CH 2 COOH, --CH 2 COONH 2 , --CH 2 COOEt, --CH 2 CONHCH 2 CH 2 NH 2 and SiR" 3 wherein R" is alkyl (2-6 C).
Claim 10
Dependent Claim
252 words
A monomer having the formula: ##STR8## wherein B is a purine or pyrimidine moiety; W 1 is H, (PO 3 ) m -2 wherein m is an integer of 1-3; a protecting group, or an intermediate moiety in the formation of an internucleotide link which when reacted with the appropriate --OH results in Z wherein Z is selected from the group consisting of P(O)O -- , P(O)S, P(O)NR 2 , P(O)R, P(O)OR', CO, and CNR 2 , wherein R is H or alkyl (1-6 C) and R' is alkyl (1-6 C); W 2 is H, PO 3 -2 a protecting group, or an intermediate moiety in the formation of an internucleotide link which when reacted with the appropriate --OH results in Z wherein Z is selected from the group consisting of P(O)O -- , P(O)S, P(O)NR 2 , P(O)R, P(O)OR', CO, and CNR 2 , wherein R is H or alkyl (1-6 C) and R' is alkyl (1-6 C); X is O, S or CR 2 wherein each R is independently H or alkyl (1-6 C); Y is selected from the group consisting of substituted or unsubstituted alkyl (2-20 C), substituted or unsubstituted alkenyl (2-20 C), substituted or unsubstituted aryl (6-20 C), wherein the substituents are selected from the group consisting of a hydroxyl, an amino, a mercaptyl, a carboxy or a keto moiety, --CH 2 COOH, --CH 2 COONH 2 , --CH 2 COOEt, --CH 2 CONHCH 2 CH 2 NH 2 and SiR" 3 wherein R" is alkyl (2-6 C).
References Cited (Backward Citations)
US4458066A
Cited
US4476301A
Cited
US4981957A
Cited
US4828979A
Cited
EP0267996A1
Cited
US4924624A
Cited
US5109126A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1998-11-13 | 1999-05-15 | 1999-11-14 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2002-11-13 | 2003-05-15 | 2003-11-14 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2006-11-13 | 2007-05-15 | 2007-11-14 | $7700.00 | Window Closed / Lapsed |